Shares of Express Scripts Holding Co (NASDAQ:ESRX) have been assigned a consensus recommendation of “Hold” from the twenty-one ratings firms that are currently covering the stock, Marketbeat Ratings reports. Two research analysts have rated the stock with a sell recommendation, twelve have issued a hold recommendation, five have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $86.05.
A number of brokerages have recently issued reports on ESRX. Credit Suisse Group lowered Express Scripts from an “outperform” rating to a “neutral” rating and lifted their price target for the stock from $90.00 to $96.50 in a research note on Tuesday, September 18th. BidaskClub raised Express Scripts from a “hold” rating to a “buy” rating in a research note on Tuesday, September 18th. ValuEngine raised Express Scripts from a “hold” rating to a “buy” rating in a research note on Monday, September 17th. Royal Bank of Canada boosted their price objective on Express Scripts to $94.00 and gave the stock an “outperform” rating in a research note on Monday, August 27th. Finally, Zacks Investment Research lowered Express Scripts from a “hold” rating to a “sell” rating in a research note on Monday, July 23rd.
Shares of NASDAQ:ESRX opened at $94.87 on Tuesday. The company has a current ratio of 0.71, a quick ratio of 0.59 and a debt-to-equity ratio of 0.69. The company has a market capitalization of $53.00 billion, a PE ratio of 13.36, a PEG ratio of 1.19 and a beta of 1.01. Express Scripts has a 1 year low of $59.17 and a 1 year high of $97.22.
In other Express Scripts news, insider Christine Houston sold 12,898 shares of Express Scripts stock in a transaction on Friday, August 10th. The stock was sold at an average price of $85.00, for a total value of $1,096,330.00. Following the sale, the insider now owns 110,908 shares in the company, valued at $9,427,180. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 0.79% of the stock is owned by insiders.
Large investors have recently bought and sold shares of the business. Omni Partners LLP raised its position in Express Scripts by 22.0% in the second quarter. Omni Partners LLP now owns 281,026 shares of the company’s stock valued at $21,698,000 after purchasing an additional 50,664 shares during the period. Marco Investment Management LLC raised its position in Express Scripts by 168.2% in the second quarter. Marco Investment Management LLC now owns 79,246 shares of the company’s stock valued at $6,119,000 after purchasing an additional 49,696 shares during the period. BlackRock Inc. raised its holdings in shares of Express Scripts by 1.5% in the 2nd quarter. BlackRock Inc. now owns 35,424,185 shares of the company’s stock valued at $2,735,103,000 after buying an additional 538,578 shares during the period. Qube Research & Technologies Ltd raised its holdings in shares of Express Scripts by 45.6% in the 2nd quarter. Qube Research & Technologies Ltd now owns 11,749 shares of the company’s stock valued at $907,000 after buying an additional 3,678 shares during the period. Finally, Commonwealth Bank of Australia raised its holdings in shares of Express Scripts by 15.6% in the 2nd quarter. Commonwealth Bank of Australia now owns 296,858 shares of the company’s stock valued at $22,915,000 after buying an additional 39,983 shares during the period. Institutional investors own 84.74% of the company’s stock.
About Express Scripts
Express Scripts Holding Company operates as a pharmacy benefit management (PBM) company in the United States and Canada. The company's PBM segment offers clinical solutions; and specialized pharmacy care, home delivery and specialty pharmacy, retail network pharmacy administration, benefit design consultation, drug utilization review, drug formulary management, public exchange, administration of group purchasing organization, and digital consumer health and drug information services.
Further Reading: Beta
Receive News & Ratings for Express Scripts Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Express Scripts and related companies with MarketBeat.com's FREE daily email newsletter.